openPR Logo
Press release

Fully Automated Chlamydia Diagnostics from ORGENTEC

06-20-2012 09:04 PM CET | Health & Medicine

Press release from: ORGENTEC Diagnostika

Tests for fully automated Chlamydia diagnostics: "Walk-Away" infectious disease diagnostics with Alegria®

Tests for fully automated Chlamydia diagnostics: "Walk-Away" infectious disease diagnostics with Alegria®

Mainz, June 19, 2012 – ORGENTEC Diagnostika (www.orgentec.com) has introduced six new tests for the diagnosis of infectious diseases. The new ELISA tests detect antibodies against Chlamydia trachomatis and Chlamydia pneumoniae. In addition, these test systems make it possible to differentiate between acute, latent, and chronic infection with these widespread bacterial pathogens.

The new tests for the serological diagnosis of Chlamydia were developed specifically for Alegria®, ORGENTEC Diagnostika’s random access analyser. The tests can be used to rapidly, automatically, and economically analyse patient samples for both species of Chlamydia. This system works equally well for individual samples or up to thirty samples in a single instrument run.

Every Alegria® Test Strip is equipped with all of the reagents needed to test a patient sample. The test kit’s individual barcode contains all of the information required for the analysis and evaluation of the ELISA. No preparation of the sample, test strip, or instrument is required before running the test.

The Anti-Chlamydia trachomatis assays use a recombinant antigen of the major outer membrane protein complex (MOMP) of Chlamydia trachomatis. In addition to the MOMP antigen, these tests use two other recombinant antigens, TARP and CPAF, which also react specifically with antibodies against Chlamydia trachomatis. The sensitivity and specificity of these tests are thus higher than those of conventional ELISAs, which only use the MOMP target antigen. TARP stands for translocated actin-recruiting protein, CPAF for chlamydial protease-like activity factor.

The antigens used for the ORGENTEC Anti-Chlamydia pneumoniae test are elementary bodies and reticulate bodies of Chlamydia pneumoniae. Special processing of the antigen significantly increases the species specificity of these tests relative to the other pathogenic Chlamydia species.

Depending on the serotype, Chlamydia trachomatis affects the mucosal epithelial cells of the urogenital and respiratory tracts as well as the conjunctival epithelial cells. Urogential infections with Chlamydia trachomatis (serotypes D-K) are among the most common sexually transmitted diseases worldwide. Both men and women are affected.

In particular in women, untreated chronic infections with Chlamydia of serotypes D-K frequently results in sterility or dangerous tubal pregnancies. Infections with Chlamydia trachomatis are often asymptomatic and stealthy, which means that primary infections are often overlooked. Patients are thus often not diagnosed and treated in a timely fashion.

Chlamydia pneumoniae can trigger pulmonary infections. Prevalence in the general population is high, reaching up to 70 percent. Asymptomatic progression of an infection with Chlamydia pneumoniae is often problematic because a primary infection may not be diagnosed until it has led to chronic conditions like asthma or COPD (COPD = chronic obstructive pulmonary disease).

ORGENTEC Diagnostika offers many laboratory tests for the fully automated diagnosis of infectious diseases. In addition to the newly introduced assays for the diagnosis of Chlamydia, they include Alegria® test systems for the serological detection of infections with the Epstein-Barr virus (EBV), measles, mumps, and herpes simplex virus (HSV-1 and HSV-2). A number of additional test systems for the laboratory diagnosis of bacterial and viral infectious diseases are currently in development, some at a very advanced stage.

When using the Alegria® Test Strips, operators are completely free in their selection of samples and can freely combine necessary analyses for autoimmune diagnostics and infectious serology. This flexibility makes the Alegria® analyser and the test systems designed for it particularly attractive for laboratories with moderate or low sample throughput or for the acute diagnosis of autoimmune or infectious diseases.

Based in Mainz, ORGENTEC Diagnostika is a global leader in the development and marketing of test systems for autoimmune diagnostics and serological tests for infectious disease. ORGENTEC has developed numerous highly specific ELISA test systems, immunoblot and immunofluorescence tests, the Alegria® random access analyser, and the rheumachec® rapid test.

ORGENTEC Diagnostika GmbH
Tobias Stolzenberg
Dr. Friederike Hammar
Carl-Zeiss-Straße 49-51
55129 Mainz, Germany
www.orgentec.com
orgentec@orgentec.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Fully Automated Chlamydia Diagnostics from ORGENTEC here

News-ID: 226163 • Views: 3960

More Releases from ORGENTEC Diagnostika

Online Immunofluorescence Guide for Diagnosis of Autoimmune Diseases
Mainz, May 09 2012 – From now on the Immunofluorescence Guide for the Modern Autoimmunity Laboratory is available as a free ebook. The online reference work with numerous pictures of immunofluorescence patterns is accessible from the ORGENTEC Diagnostika website (www.orgentec.com) and from the website of the GRÜNE CLUB AUTOIMMUN (www.der-gruene-club.at). The online guide is public domain without login or registration. Whether it is the immunofluorescence pattern of antinuclear antibodies (ANA) on
Autoantibody Diagnostics in Autoimmune Liver Diseases
ORGENTEC Diagnostika (www.orgentec.com) has developed four new laboratory tests for the diagnosis of autoimmune liver diseases. These tests are now on the market. They are based on ELISA technology and were specifically developed for fully automated analysis with Alegria®. The new tests systems, called Anti-Sp100, Anti-gp210, Anti-LKM-1, and Anti-SLA, reliably detect specific autoantibodies that are characteristic of various autoimmune liver diseases. The tests thus also allow for reliable differentiation between these
A New Healthcare App: ORGENTEC Autoimmunity Guide
The ORGENTEC Autoimmunity Guide is now available for download from the Apple iTunes App Store and the Android Market. This app from Mainz-based ORGENTEC Diagnostika GmbH (www.orgentec.com) makes it possible to call up information about autoimmune diseases easily and comfortably from a smartphone or tablet – precisely, compactly, and without extensive searching. The ORGENTEC app offers comprehensive information about the diagnosis and monitoring of autoimmune diseases by means of antibody detection.
Autoimmune Disease Diagnostics: High Sensitivity ACPA Test for Rheumatoid Arthri …
Mainz, November 16, 2011 – For Medica 2011, ORGENTEC Diagnostika presents a new laboratory test for the diagnosis of rheumatism. The highly sensitive Anti-CCP hs (high sensitive)® test makes possible the early diagnosis of rheumatoid arthritis (RA), which in turn allows for successful treatment of this autoimmune disease. The new Anti-CCP hs (high sensitive)® test is the most recent development in the area of ACPA testing. This innovate enzyme immunoassay combines

All 5 Releases


More Releases for Chlamydia

Chlamydia Infections-Pipeline Review H2 2018
Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine. Report Highlights Publisher's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections-Pipeline Review, H2 2018,
Chlamydia Infections Therapeutic Pipeline Market Review, H1 2018
Summary Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine. Report Highlights Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections - Pipeline Review, H1 2018,
Chlamydia Diagnostics Market To Be At Forefront By 2019
Some of the major players in Chlamydia Diagnostic Market include Abbott Laboratories, Bio-Rad, Novartis Diagnostics, Roche, Wallac, ID Biomedical and others. Chlamydia is one of the most widespread sexually transmitted diseases. It is caused by bacteria named Chlamydomonas trachomatis. This disease is more common in females as compared to male population. In addition, the disease is more prevalent in people who are older than 25 years due to multiple sex and
Chlamydia Infections Market Pipeline Review, H2 2017
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections - Pipeline Review, H2 2017, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape. Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex
Chlamydia Infections Global Clinical Trials Review H1 2017
ReportsWeb.com published “Chlamydia Infections Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Publisher's clinical trial report "Chlamydia Infections Global Clinical Trials Review H1 2017" provides an overview of Chlamydia Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Chlamydia Infections.
Chlamydia Infections - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Chlamydia Infections - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections - Pipeline Review, H1 2017, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape. Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from